SignPath Pharma Reports Extremely Beneficial Blood Level Results of Its Phase 1b Clinical Trials of Liposomal Curcumin in Advanced Cancer Patients as Published in the Cancer Research Journal “Cancer Chemotherapy and Pharmacology”

SALT LAKE CITY–(BUSINESS WIRE)–#cancer—SignPath
Pharma Inc. reported in the October issue of “Cancer
Chemotherapy and Pharmacology”*, a leading cancer journal, the final
results of a Phase 1b cancer study of proprietary Liposomal Curcumin.
The study showed that the Liposomal Curcumin formulation (Lipocurc™) can
result in blood levels up to 1000 times that achieved with oral
curcumin. In addition, no major toxicity was noted at these high blood
levels. Specifically no toxicity was found in kidney, lung, liver and
heart organs. The study involved 31 heavily pretreated cancer patients.
Significant tumor marker responses and transient clinical benefit were
also observed.

Curcumin has long been of interest as an anti-inflammatory modulator and
as a potential therapeutic agent for cancer, central nervous system and
other diseases. Orally administered curcumin has not been able to
achieve sufficient blood levels. LipoCurc™ addresses these limitations
and has the potential to be a potent, non-toxic modality for treating
these dire conditions.

Although Phase 1b studies are designed to determine safety of a drug and
not to measure efficacy, two patients had obvious and important signs of
tumor response. One was a 75 year old male with colon cancer, who had
previously failed seven multi-drug chemotherapy combinations. On
Lipocurc™, his CEA, a tumor-marker which is elevated in patients with
cancer, fell from above 18,000 to just above 6,000, and he showed
clinical improvement. The other was a patient with prostate cancer who
had previously failed radiation therapy as well as six chemotherapy
combinations. His PSA level fell from 649 to 350 and he also showed
clinical improvement.

On the basis of these results, SignPath is planning several phase 2
trials to test the efficacy of Lipocurc™ against specific cancer types.
Trials are planned in patients with glioblastoma, in multiple myeloma,
and in mesothelioma. Dr. Peter Sordillo, Chief Medical Officer of
SignPath Pharma, states “We are very pleased with the Phase 1b results
with LipoCurc™ and look forward to testing it in Phase 2 clinical
trials. We believe LipoCurc™ has the potential to be a new potent,
non-toxic therapeutic strategy for cancer and other diseases.”

SignPath
Pharma, Inc. is a clinical stage biopharmaceutical company
developing two major drug platforms:

• LipoCurc™ for cancer, neurodegenerative diseases and sepsis.
• SPP 4040 for prevention of drug-induced cardiac arrhythmias, and
  prevention of heart damage and congestive heart failure secondary to
  chemotherapy.

*October 2018, Volume 82, Issue 4, pp
695–706

Contacts

SignPath Pharma, Inc.
Peter P. Sordillo, M.D., PhD
Vice-President
and Chief Scientific Officer
psordillo@signpathpharma.com
www.signpathpharma.com